. Author manuscript; available in PMC: 2023 May 1.

Published in final edited form as: Trends Cancer. 2022 Feb 18;8(5):397–403. doi: 10.1016/j.trecan.2022.01.004

Table 1.

Summary of clinical trials for signaling mediators of cancer cachexia

Clinical Trial	Agent	Target	Population	Phase	Status
NCT01505530 ⁱ	Landogrozumab (LY2495655)	myostatin	pancreatic cancer patients	II	Completed
NCT02262455 ⁱⁱ	STM 434	Activin A	ovarian cancer patients	I	Completed
NCT04068896 ⁱⁱⁱ	NGM120	GDF15	advanced solid tumor and pancreatic cancer patients	I/II	Recruiting
NCT04803305 ^iv	PF-06946860	GDF15	certain advanced solid tumor patients with anorexia	I	Recruiting
NCT04815551 ^v	AV-380	GDF15	healthy subjects	I	Active, not recruiting
NCT04725474 ^vi	CTL-002	GDF15	advanced solid tumor patients	I	Recruiting

Roman numerals following the Clinical Trial Identifier refer to additional information under Resources.